Moderate-to-severe Plaque Psoriasis Clinical Trial
Official title:
Prospective Observational Study With Retrospective Part to Evaluate Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Moderate-to-severe Plaque Psoriasis
Multicenter, non-interventional, cohort study in pediatric patients with moderate to severe plaque-type psoriasis. Retrospective data collection is planned at patients' inclusion.
This observational study will be performed at healthcare facilities treating pediatric psoriasis patients. The study population will consist of a representative group of pediatric patients with moderate-to-severe plaque psoriasis for whom routine treatment with secukinumab according to the approved national label is initiated during 4 to 16 weeks Retrospective data collection is planned at patients' inclusion. Prospective data collection will continue during follow-up routine visits until secukinumab discontinuation or maximum duration of follow-up for 104 weeks after index date. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05787236 -
A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting
|
||
| Active, not recruiting |
NCT04612699 -
A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis
|
Phase 2 | |
| Not yet recruiting |
NCT06258668 -
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
|
||
| Recruiting |
NCT06182384 -
A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices
|
Phase 1 | |
| Recruiting |
NCT03710681 -
A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis
|
Phase 1 | |
| Not yet recruiting |
NCT04839016 -
Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis
|
Phase 3 |